China has become the first global market where Long-Acting Recombinant Human Growth Hormone (LAGH) has officially overtaken daily injections in total patient volume. Domestic innovations have produced PEGylated formulations that require only one subcutaneous injection per week.

For the Chinese patient, this is transformative. Due to the high academic pressure and long school hours (often including boarding), daily injections were frequently missed, leading to poor treatment outcomes. The weekly "steady-state" release provided by domestic LAGH ensures that the child maintains a consistent level of Insulin-like Growth Factor 1 (IGF-1), leading to more predictable height velocity and better psychological compliance among adolescents.